Can Traditional Chinese Medicine Reduce Febrile Neutropenia Risks in Cancer Patients?

Febrile neutropenia (FN) is a serious condition affecting around 7 to 8 in every 1,000 cancer patients. It involves a high fever—over 38.3°C—and dangerously low neutrophil levels, leading to a mortality rate of nearly 9.5%. When it occurs, FN demands urgent medical attention, often disrupting chemotherapy schedules and increasing pressure on healthcare systems.

FN arises when chemotherapy weakens the immune system, leaving patients vulnerable to infections. Beyond the immediate health risks, delays in treatment reduce the effectiveness of cancer therapy. Traditional Chinese Medicine (TCM) offers a complementary approach to managing these challenges.

TCM views FN through the lens of vitality and balance, focusing on deficiencies in qi, blood, and yang. Practitioners aim to restore equilibrium by strengthening these elements and supporting key organs. Studies suggest this method can ease chemotherapy side effects, including anaemia, low white blood cell counts, nausea, and nerve damage. Research has shown promising results. A retrospective analysis found that patients pretreated with TCM saw FN rates drop from 71% to 43%. Another study reported that a specific TCM formula cut fever duration by more than two days and sped up neutrophil recovery by four days. Importantly, TCM treatments are generally well-tolerated, with mild and short-lived side effects and no evidence of raising secondary cancer risks.

The findings highlight TCM's potential as a supportive therapy for cancer patients at risk of FN. By reducing fever duration and aiding recovery, it may help maintain chemotherapy schedules and ease the burden on healthcare services. Further research could solidify its role in managing treatment-related complications.